CEO Mike Nassif was paid $8,693,916 in fiscal year 2026, the 42nd percentile of its disclosed peer group (SEC filing 0001193125-26-360742 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$8,693,916 Mike Nassif total, FY2026 | 42nd CEO pay percentile vs peers | 152:1 CEO-to-median pay ratio | 98.38% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
NEOG's next annual pay disclosure, estimated July 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mike Nassif | $630,769 | $500,000 | $3,250,000 | $3,250,000 | $1,000,000 | $0 | $63,146 | $8,693,916 |
| President & Chief Executive Officer | ||||||||
| R. Bryan Riggsbee | 334,615 | 250,000 | 1,125,000 | 1,125,000 | 480,000 | — | 24,437 | 3,339,053 |
| Senior Vice President | ||||||||
| Tamara Ranalli | 188,462 | 350,000 | 750,000 | 750,000 | 99,315 | — | 11,073 | 2,148,850 |
| Senior Vice President and General Manager, Global Food Safety | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Mike Nassif | $8,693,916 | — | — | — |
| R. Bryan Riggsbee | 3,339,053 | — | — | — |
| Tamara Ranalli | 2,148,850 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Neogen's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper NEOG reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses NEOG in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NEOG in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2026 total |
|---|---|---|
| Aashima Gupta | Independent Director | $310,000 |
| Andrea F. Wainer | Independent Director | $381,804 |
| Avi Pelossof | Independent Director | $287,244 |
| Catherine E. Woteki, Ph.D | Independent Director | $317,500 |
| James C. Borel | Chair of the Board | $367,500 |
| Jeffrey D. Capello | Independent Director | $345,000 |
| Raphael A. Rodriguez | Independent Director | $315,625 |
| Ronald D. Green, Ph.D | Independent Director | $317,500 |
| Thierry L. Bernard | Former director (through FY2026) | $335,000 |
| William T. Boehm, Ph.D | Former director (through FY2026) | $27,500 |
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Avi Pelossof | Director | 2026-10-01 | A | 20,558 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Avi Pelossof | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrea F. Wainer | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| James C. Borel | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James C. Borel | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey D. Capello | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Aashima Gupta | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Catherine E. Woteki | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Raphael A. Rodriguez | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Ronald D. Green | Director | 2026-10-01 | A | 20,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ronald D. Green | Director | 2026-10-01 | A | 9,804 | 12 | 120,001 | Common | Form 4 ↗ |
| Mike Nassif | Director | 2026-10-09 | A | 505 | 12 | 6,035 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adent | Option | 51,534 | 28.4 | — |
| Adent | Option | 625,001 | 13.28 | — |
| Adent | Option | 465,501 | 15.48 | — |
| Adent | Option | 261,545 | 16.79 | — |
| Rocklin | Option | 11,779 | 28.4 | — |
| Rocklin | Option | 120,537 | 13.28 | — |
| Rocklin | Option | 109,725 | 15.48 | — |
| Rocklin | Option | 97,145 | 16.79 | — |
| Rocklin | Option | 58,341 | 5.69 | — |
| Rocklin | Option | 102,560 | 5.43 | — |
Neogen's executive compensation program is designed to align pay outcomes with Company performance, strategic execution, and long-term shareholder value creation. A substantial portion of each NEO's compensation is variable and performance-based, ensuring that executive rewards are linked to the achievement of key financial, operational, and shareholder objectives.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Farient Advisors, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-10-01 | 151,434,206 | 2,498,510 | 2,677,583 | 98.38% | Passed |
| 2025 | 2025-10-23 | 167,126,873 | 17,679,601 | 412,667 | 90.43% | Passed |
| 2024 | 2024-10-24 | 96,518,858 | 101,431,438 | 677,525 | 48.76% | Failed |
| 2023 | 2023-10-25 | 188,942,194 | 6,399,654 | 294,342 | 96.72% | Passed |
| 2022 | 2022-10-06 | 74,522,788 | 3,427,649 | 311,060 | 95.6% | Passed |
| 2021 | 2021-10-07 | 91,114,077 | 3,300,741 | 204,853 | 96.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-10-01 | 98.38%a |
| 2025 | 2025-10-23 | 90.43%b |
| 2024 | 2024-10-24 | 48.76%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast so will not have any effect on the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as votes cast so will not have any effect on the outcome of this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 152 : 1 |
|---|---|
| CEO total compensation | $8,863,146 |
| Median employee compensation | $58,231 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrea F. WainerIndependent · Audit · Science, Technology and Innovation | $72,500 | $154,652 | $154,652 | — | $0 | $381,804 |
| James C. BorelIndependent · Board Chair · Audit · Governance and Sustainability | 127,500 | 120,000 | 120,000 | — | 0 | 367,500 |
| Jeffrey D. CapelloIndependent · Audit (Chair) · Compensation and Talent Management | 105,000 | 120,000 | 120,000 | — | 0 | 345,000 |
| Thierry L. BernardIndependent · Compensation and Talent Management · Governance and Sustainability · Departed during FY | 95,000 | 120,000 | 120,000 | — | 0 | 335,000 |
| Catherine E. Woteki, Ph.DIndependent · Compensation and Talent Management (Chair) · Science, Technology and Innovation | 77,500 | 120,000 | 120,000 | — | 0 | 317,500 |
| Ronald D. Green, Ph.DIndependent · Governance and Sustainability (Chair) · Science, Technology and Innovation | 77,500 | 120,000 | 120,000 | — | 0 | 317,500 |
| Raphael A. RodriguezIndependent · Compensation and Talent Management · Science, Technology and Innovation (Chair) | 75,625 | 120,000 | 120,000 | — | 0 | 315,625 |
| Aashima GuptaIndependent · Governance and Sustainability · Science, Technology and Innovation | 70,000 | 120,000 | 120,000 | — | 0 | 310,000 |
| Avi PelossofIndependent · Audit · Compensation and Talent Management | 47,244 | 120,000 | 120,000 | — | 0 | 287,244 |
| William T. Boehm, Ph.DIndependent · Audit (Chair) · Compensation and Talent Management · Departed during FY | 27,500 | 0 | 0 | — | 0 | 27,500 |
| Mike NassifEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 7,500 |
| Stock ownership guideline | $275,000 |
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $775,369 |
| Equity awards (grant-date value) | $1,114,652 |
| All other compensation | $0 |
| Total cost of the board | $1,890,021 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Neogen names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Neogen.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exact Sciences Corporation | 2024 | Kevin Conroy | $1,083,368 | $13,496,138 | $0 | $712,329 | $15,539,378 |
| 2 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 3 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 4 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 5 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 6 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 7 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 8 | Sotera Health Company | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 9 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 10 | Maravai LifeSciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 11 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 12 | Neogen | 2026 | Mike Nassif | 630,769 | 3,250,000 | 3,250,000 | 1,000,000 | 8,693,916 |
| 13 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 14 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 15 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 16 | Mettler-Toledo International, Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
| 17 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 18 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 19 | Bruker Corporation | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| 20 | OraSure Technologies, Inc. | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Neogen | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Azenta, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| Bruker Corporation | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| iRhythm Technologies, Inc. | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| Maravai LifeSciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Mettler-Toledo International, Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| OraSure Technologies, Inc. | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sotera Health Company | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity, LLP |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mike Nassif | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Executive Compensation”. As printed: 8,693,916. Filing ↗machine: span 1672214–1672223 |
| 2 | Section 01, R. Bryan Riggsbee | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Executive Compensation”. As printed: 3,339,053. Filing ↗ |
| 3 | Section 01, Tamara Ranalli | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Executive Compensation”. As printed: 2,148,850. Filing ↗ |
| 4 | Section 07, pay ratio | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “CEO Pay Ratio”. As printed: 152 : 1. Filing ↗ |
| 5 | Section 08, Andrea F. Wainer | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 381,804. Filing ↗ |
| 6 | Section 08, James C. Borel | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 367,500. Filing ↗ |
| 7 | Section 08, Jeffrey D. Capello | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 345,000. Filing ↗ |
| 8 | Section 08, Thierry L. Bernard | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 335,000. Filing ↗ |
| 9 | Section 08, Catherine E. Woteki, Ph.D | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 317,500. Filing ↗ |
| 10 | Section 08, Ronald D. Green, Ph.D | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 317,500. Filing ↗ |
| 11 | Section 08, Raphael A. Rodriguez | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 315,625. Filing ↗ |
| 12 | Section 08, Aashima Gupta | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 310,000. Filing ↗ |
| 13 | Section 08, Avi Pelossof | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 287,244. Filing ↗ |
| 14 | Section 08, William T. Boehm, Ph.D | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 27,500. Filing ↗ |
| 15 | Section 08, Mike Nassif | DEF 14A | 2026-08-21 | 0001193125-26-360742 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 02, Avi Pelossof 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Avi Pelossof 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Aashima Gupta 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Andrea F. Wainer 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Andrea F. Wainer 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, James C. Borel 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, James C. Borel 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Jeffrey D. Capello 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Jeffrey D. Capello 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Aashima Gupta 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Catherine E. Woteki 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Catherine E. Woteki 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Raphael A. Rodriguez 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Raphael A. Rodriguez 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Ronald D. Green 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Ronald D. Green 2026-10-01 | Form 4 | 2026-10-02 | 0000711377-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Mike Nassif 2026-10-09 | Form 4 | 2026-10-09 | 0000711377-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 06, 2026 vote | Form 8-K | 2026-10-07 | 0001193125-26-416247 | Item 5.07 · say-on-pay result. As reported: 98.38% (votes for as printed: 151,434,206). Filing ↗ |
| 34 | Section 06, 2025 vote | Form 8-K | 2025-10-27 | 0001193125-25-250823 | Item 5.07 · say-on-pay result. As reported: 90.43% (votes for as printed: 167,126,873). Filing ↗ |
| 35 | Section 06, 2024 vote | Form 8-K | 2024-10-28 | 0000950170-24-117710 | Item 5.07 · say-on-pay result. As reported: 48.76% (votes for as printed: 96,518,858). Filing ↗ |
| 36 | Section 09b board cost (computed) | Computed | — | — | Cash 775,369 + equity 1,114,652 + all other 0 = 1,890,021, summed across the director compensation table rows.machine: formula: Σ = 1,890,021 |
| 37 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 38 | Charles River Laboratories International, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 39 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 40 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 41 | Waters Corporation, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149657 | CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533 |
| 42 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 43 | iRhythm Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 44 | Sotera Health Company, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001104659-26-040937 | CEO total compensation as printed in Sotera Health Company's own proxy. As printed: 10,656,063. Filing ↗machine: span 996859–996869 |
| 45 | Azenta, Inc., Section 10b CEO total | DEF 14A | 2025-12-18 | 0001140361-25-046064 | CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. Filing ↗machine: r2 · c22 · span 1247118–1247129 |
| 46 | Maravai LifeSciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 47 | NeoGenomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001077183-26-000014 | CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469 |
| 48 | Neogen (subject), Section 10b CEO total | DEF 14A | 2026-08-21 | 0001193125-26-360742 | CEO total compensation as printed in Neogen's own proxy. As printed: 8,693,916. Filing ↗machine: span 1672214–1672223 |
| 49 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 50 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 51 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 52 | Mettler-Toledo International, Inc., Section 10b CEO total | DEF 14A | 2026-03-18 | 0001174947-26-000389 | CEO total compensation as printed in Mettler-Toledo International, Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538 |
| 53 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 54 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 55 | Bruker Corporation, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-151305 | CEO total compensation as printed in Bruker Corporation's own proxy. As printed: 4,706,388. Filing ↗machine: t77 · r2 · c18 · span 987303–987312 |
| 56 | OraSure Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 57 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 58 | Section 10a, Azenta, Inc. reciprocity | DEF 14A | — | 0001140361-25-046158 | Azenta, Inc. names Neogen in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 59 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 60 | Section 10a, Bruker Corporation reciprocity | DEF 14A | — | 0001193125-26-151305 | Bruker Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 61 | Section 10a, Charles River Laboratories International, Inc. reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories International, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 62 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 63 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 64 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 65 | Section 10a, iRhythm Technologies, Inc. reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 66 | Section 10a, Maravai LifeSciences Holdings, Inc. reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai LifeSciences Holdings, Inc. names Neogen in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 67 | Section 10a, Mettler-Toledo International, Inc. reciprocity | DEF 14A | — | 0001174947-26-000389 | Mettler-Toledo International, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 68 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 69 | Section 10a, NeoGenomics, Inc. reciprocity | DEF 14A | — | 0001077183-26-000014 | NeoGenomics, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 70 | Section 10a, OraSure Technologies, Inc. reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 71 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 72 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names Neogen in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 73 | Section 10a, Sotera Health Company reciprocity | DEF 14A | — | 0001104659-26-040937 | Sotera Health Company's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
| 74 | Section 10a, Waters Corporation reciprocity | DEF 14A | — | 0001193125-26-149657 | Waters Corporation's most recent proxy was read; its disclosed peer group does not include Neogen. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.